TC Biopharm submits IND application to FDA for use of TCB-008 to treat AML

TC BioPharm announced submission of an Investigational New Drug application to the U.S. FDA for the use of TCB-008 in the treatment of relapse/refractory Acute Myeloid Leukemia. TCB-008, an allogeneic unmodified gamma delta t-cell, is the company’s lead product and is currently in Phase 2b trials in the U.K. for the treatment of AML. The IND application leverages pioneering research on the use of Gamma Deltas in the treatment of relapse/refractory Acute Myeloid Leukemia. TCB-008 has been designated Orphan Drug Status in the treatment arena of AML previously.